| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 84601 |
Fmoc-Gln(Trt)-PAB-OH， ADC试剂 |
187 |
kx |
2024-12-19 |
| 84602 |
CAS: 2994332-18-0 ，DBCO-C4-Val-Cit-PABC-PNP，二苯并环辛炔-C4-缬氨酸-瓜氨酸-PABC-对硝基苯基磷酸酯 |
163 |
WYQ |
2024-12-19 |
| 84603 |
cas:159857-60-0，Fmoc-Lys(MMt)-OH，N-[(9H-芴-9-基甲氧基)羰基]-N'-[(4-甲氧基苯基)二苯基甲基]-L-赖氨酸 |
274 |
kx |
2024-12-19 |
| 84604 |
DBCO-PEG3-Val-Cit-PAB-PNP，二苯并环辛炔-三聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
198 |
WYQ |
2024-12-19 |
| 84605 |
NOTA-anti-HER2 NOTA标记抗人表皮生长因子受体2型(HER2)纳米体 |
188 |
h |
2024-12-19 |
| 84606 |
cas:186023-44-9 Fmoc-Ala-Pro-OH |
219 |
zyl |
2024-12-19 |
| 84607 |
TCO-PEG4-Val-Cit-PAB-PNP，反式环辛烯-四聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
178 |
WYQ |
2024-12-19 |
| 84608 |
Boc-Val-Cit CAS:870487-08-4 |
260 |
zyl |
2024-12-19 |
| 84609 |
DOTA-Bn-FGK-Fab DOTA标记抗体片段 |
192 |
h |
2024-12-19 |
| 84610 |
cas:252554-78-2，Fmoc-Ala-Ser (Psi(Me,Me)pro)-OH，(4S)-3-[(2S)-2-[[(9H-芴-9-甲氧基)羰基]氨基]-1-氧代丙基]-2,2-二甲基-4-恶唑烷羧酸 |
156 |
kx |
2024-12-19 |
| 84611 |
DOTA-Nal3-Octreotide DOTANOC DOTA-Nal3-奥曲肽 |
161 |
h |
2024-12-19 |
| 84612 |
cas:2413428-36-9，MC-Gly-Gly-Phe-Gly，(S)-5-苄基-18-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)-4,7,10,13-四氧代-3,6,9,12-四氮杂十八烷-1-酸 |
155 |
kx |
2024-12-19 |
| 84613 |
MC-Val-Cit-PAB-PNP CAS:159857-81-5 |
253 |
zyl |
2024-12-19 |
| 84614 |
cas:2353409-52-4，Mal-amido-PEG8-Val-Gly-PAB-OH，马来酰亚胺-酰胺-八聚乙二醇-VAL-GLY-PAB-羟基 |
121 |
kx |
2024-12-19 |
| 84615 |
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB CAS:2055042-69-6 |
135 |
zyl |
2024-12-19 |
| 84616 |
cas:1895916-22-9，MC-Val-Ala-OH， ADC试剂 |
149 |
kx |
2024-12-19 |
| 84617 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，MC-VAL-CIT-阿霉素 |
111 |
kx |
2024-12-19 |
| 84618 |
DOTA−Gal-NAPamide DOTA−Gal-纳帕胺 |
131 |
h |
2024-12-19 |
| 84619 |
DOTA-peptide-Lym-1 radioimmunotherapy DOTA-肽-Lym-1 |
156 |
h |
2024-12-19 |
| 84620 |
N-DBCO-N-bis(PEG2-amide-PEG4-Val-cit-PAB-MMAE)， N-二苯并环辛炔-N-双(二聚乙二醇-酰胺-四聚乙二醇-VAL-CIT-PAB-MMAE) |
166 |
kx |
2024-12-19 |
| 84621 |
DOTA-dGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 |
203 |
h |
2024-12-19 |
| 84622 |
DOTA-MGO DOTA-DGlu-(Glu)s-minigastrin |
139 |
h |
2024-12-19 |
| 84623 |
cas:2762518-86-3，NHS Ester-PEG4-Val-Cit-PAB-MMAE， ADC试剂 |
184 |
kx |
2024-12-19 |
| 84624 |
DOTA-scFv-anti-PSMA DOTA-scFv-抗PSMA脂质纳米粒(LNPs) |
199 |
h |
2024-12-19 |
| 84625 |
cas:2353409-45-5，BCN-PEG3-Val-Cit-PFP Ester， ADC试剂 |
158 |
kx |
2024-12-19 |
| 84626 |
cas:2112738-13-1，Mal-amido-PEG2-Val-Cit-PAB-PNP， ADC试剂 |
128 |
kx |
2024-12-19 |
| 84627 |
cas:2055041-39-7，Mal-PEG4-Val-Cit-PAB-OH， ADC试剂 |
182 |
kx |
2024-12-19 |
| 84628 |
cas:2055024-62-7，NH2-PEG3-Val-Cit-PAB-OH， ADC试剂 |
224 |
kx |
2024-12-19 |
| 84629 |
Fmoc-PEG3-Val-Cit，N-芴甲氧羰基-三聚乙二醇-VAL-CIT |
183 |
kx |
2024-12-19 |
| 84630 |
DOTA-anti-VLA-4 |
163 |
h |
2024-12-19 |
| 84631 |
DOTA-glycylglycylglycyl-l-p-isothiocyanatophenylalanine amide |
154 |
h |
2024-12-19 |
| 84632 |
CAS: 2748039-76-9， Alkyne-Val-Cit-PAB-FAM，炔-Val-Cit-PAB-FAM |
150 |
WYQ |
2024-12-19 |
| 84633 |
CAS:646502-53-6 MC-Val-Cit-PAB-MMAE的结构式 |
203 |
zyl |
2024-12-19 |
| 84634 |
Amino-PEG2-VG-N-Bis(PEG1-azide)，氨基-二聚乙二醇-VG-N-双（一聚乙二醇-叠氮） |
164 |
WYQ |
2024-12-19 |
| 84635 |
Azido-PEG8-Val-Cit-PAB-PNP，C34H47N9O12 |
147 |
WYQ |
2024-12-19 |
| 84636 |
化合物：TCO-MMAE，反式环辛烯-MMAE（其中MMAE为单甲基澳瑞他汀E的缩写） |
233 |
WYQ |
2024-12-19 |
| 84637 |
cas:2748039-77-0，Alkyne-Val-Cit-PAB-PNP，炔-VAL-CIT-PAB-PNP 酯 |
141 |
kx |
2024-12-19 |
| 84638 |
endo BCN-PEG3-Val-Cit，endo BCN-聚乙二醇3-缬氨酸-瓜氨酸，CAS号：1263166-91-1 |
201 |
WYQ |
2024-12-19 |
| 84639 |
cas:1803279-86-8，DBCO-C4-SulfoNHS ester， ADC试剂 |
129 |
kx |
2024-12-19 |
| 84640 |
Mal-PEG8-Val-Cit-PAB-MMAE CAS:2353409-69-3 |
181 |
zyl |
2024-12-19 |
| 84641 |
159857-80-4，MC-Val-Cit-PAB-OH，MC-VAL-CIT-PAB中间体 |
130 |
kx |
2024-12-19 |
| 84642 |
氨基-四聚乙二醇-Val-Cit-PAB-MMAE，Amino-PEG4-Val-Cit-PAB-MMAE，ADC定制 |
123 |
wyh |
2024-12-19 |
| 84643 |
CAS: 2748039-77-0，化合物：Alkyne-Val-Cit-PAB-PNP |
154 |
WYQ |
2024-12-19 |
| 84644 |
MAC glucuronide linker-2 CAS:229977-57-5 |
221 |
zyl |
2024-12-19 |
| 84645 |
DOTA-cPAM4 DOTA标记PAM4抗体 |
115 |
h |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询